Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
April 02, 2024 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., April 02, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through...
Beacon Therapeutics launches with £96 million ($120 million) to develop a new generation of gene therapies for retinal diseases resulting in blindness
June 12, 2023 02:00 ET
|
Beacon Therapeutics
PRESS RELEASE Beacon Therapeutics launches with £96 million ($120 million) to develop a new generation of gene therapies for retinal diseases resulting in blindness New leading gene therapy company...
Inherited Retinal Diseases Market to Perceive Highest CAGR of 7.9 by 2029, Size, Share, Trends, Key Drivers, Growth, Challenges and Opportunity Forecast
May 23, 2023 00:30 ET
|
Data Bridge Market Research
OAKLAND, May 23, 2023 (GLOBE NEWSWIRE) -- Data Bridge Market Research's latest report, "Inherited Retinal Diseases Market" provides a thorough analysis of growth strategies, drivers, opportunities,...
Clearside Biomedical Announces First Quarter 2023 Financial Results and Provides Corporate Update
May 11, 2023 07:05 ET
|
Clearside Biomedical, Inc.
- Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Expected to Open Enrollment in Q2 2023 - - Positive Safety Data, Duration and Biologic Effect of CLS-AX Over 6 Months in OASIS Phase 1/2a Extension...
Surrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline Updates
May 10, 2023 16:05 ET
|
Surrozen, Inc.
Enrollment ongoing in SZN-043 Phase 1a clinical trial in people with chronic liver disease and in healthy volunteers with safety data expected by the end of 2023 Enrollment ongoing in SZN-1326 Phase...
Lighthouse Guild and Bionic Sight Announce Partnership to Expand Treatment Options for People Who Are Blind
November 29, 2022 09:00 ET
|
Lighthouse Guild
New York, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Lighthouse Guild, the leading not-for-profit vision and healthcare organization, and Bionic Sight, the developer of treatments and technologies for...
Clearside Biomedical Announces Third Quarter 2022 Financial Results and Provides Corporate Update
November 09, 2022 07:15 ET
|
Clearside Biomedical, Inc.
- Favorable Safety Results, Durability and Biologic Effect Observed in Cohorts 3 and 4 of CLS-AX OASIS Phase 1/2a Trial - - Recent Positive Data Presentations Highlight the Potential...
Clearside Biomedical Announces Positive Results in Safety, Durability and Biologic Effect in OASIS Phase 1/2a Clinical Trial of Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD Patients
November 09, 2022 07:05 ET
|
Clearside Biomedical, Inc.
- Primary Safety Endpoint Achieved at all Timepoints with All Doses Well-Tolerated and No Treatment Related or Serious Adverse Events - - Cohorts 3 and 4 Demonstrated Promising Signs of Durability,...
Macular Degeneration Treatment Market, 2022: Industry surge ahead at a CAGR of 7.4% to reach US$ 18.8 Bn in 2032 - Persistence Market Research
November 03, 2022 09:30 ET
|
Persistence Market Research
New York , Nov. 03, 2022 (GLOBE NEWSWIRE) -- The global macular degeneration treatment market recorded a CAGR of 6.2% in the last 9 years from 2012 to 2021 and reached a market value of around US$...
Ocugen, Inc. to Present Preclinical Results at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting
April 29, 2022 11:36 ET
|
Ocugen
MALVERN, Pa., April 29, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing and commercializing novel gene therapies, biologicals and...